With no biology degree and just $3,000, he designed a personalized mRNA vaccine in a world first. Moderna and Merck are ...

In MS trials, investigators are steering those cells toward B‑cell populations that appear to be driving inflammation.

For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...

CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...

Explore the latest colorectal cancer treatment advances, from precision oncology and immunotherapy to ADCs, bispecifics, and ...

A personalized peptide vaccine slashed prostate-specific antigen levels by as much as 99.6% in some men with advanced ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

The FDA has acknowledged receipt of the supplemental Biologics License Application (sBLA) for nogapendekin alfa inbakicept-pmln (Anktiva) plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive ...

ImmunityBio, Inc. (NASDAQ:IBRX) is among the 12 Best Performing Stocks in February. On March 4, 2026, Piper Sandler analyst Patrick Soon-Shiong increased ImmunityBio, Inc. (NASDAQ:IBRX)’s price ...

Immune checkpoint inhibitors targeting PD-1 and PD-L1 have revolutionized cancer therapy, delivering long-term survival benefits in several malignancies.

Laryngeal cancers account for a significant proportion of head-and-neck malignancies and are linked to smoking and alcohol use. These tumours can develop in ...